Lipid Effects of Psychiatric Medications

Nonstatin Drugs (WB Borden, Section Editor)

DOI: 10.1007/s11883-012-0292-6

Cite this article as:
Watanabe, J., Suzuki, Y. & Someya, T. Curr Atheroscler Rep (2013) 15: 292. doi:10.1007/s11883-012-0292-6
Part of the following topical collections:
  1. Topical Collection on Nonstatin Drugs


People with schizophrenia have higher rates of medical illness and mortality than the general population. Cardiovascular disease is a major contributor to premature death in patients with schizophrenia. There has been an increase literature discussing the high prevalence of dyslipidemia, which is one of risk factors for cardiovascular disease, induced by second generation antipsychotic agents. Depression is associated with increased risks of diabetes, hypertension, cardiovascular disease. However, those may not be secondary to the use of antidepressant agents. In order to reduce the risk of cardiovascular disease in patients with schizophrenia receiving antipsychotic agents, obtaining fasting lipid measurements at regular intervals is needed. Further investigations are needed to evaluate the effects of antidepressive agents on lipid profiles.


First generation antipsychotic agents Second generation antipsychotic agents Antidepressive agents Dyslipidemia Lipid profiles Monitoring 

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Junzo Watanabe
    • 1
  • Yutaro Suzuki
    • 1
  • Toshiyuki Someya
    • 1
  1. 1.Department of PsychiatryNiigata University Graduate School of Medical and Dental SciencesNiigataJapan

Personalised recommendations